Optum Rx, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in ...

Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

Journavx will likely follow the trajectory ... The drug was approved for up to two weeks of pain management. Suzetrigine is a sodium channel blocker that blocks a specific sodium channel called ...

Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...

A James Island pharmacist is looking to the future of pain management thanks to the Food and Drug Administration approving a new treatment.

The U.S. Food and Drug Administration (FDA) has approved Journavx, the first opioid-free prescription drug for moderate to ...

The drug, called Journavx, is part of a broader effort by the Food and Drug Administration and healthcare providers to develop non-addictive pain management options. Journavx is the first in a new ...

“I believe JOURNAVX could redefine the management of pain and become a foundational treatment option for people with all types of moderate-to-severe acute pain, where options aside from opioids ...

Arbuckle claims, as industry executives often do, that his team has had fruitful conversations with these stakeholders, that they appreciate Journavx may fill a major gap in pain management.

Tris Pharma’s opioid alternative has scored a third win in a trio of clinical trials, providing the biotech with the data ...

RICHMOND, Va. (WRIC) — The U.S. Food and Drug Administration (FDA) has approved Journavx, the first opioid-free prescription drug for moderate to severe acute pain in more than 20 years.